0001062993-23-009245.txt : 20230417 0001062993-23-009245.hdr.sgml : 20230417 20230417192409 ACCESSION NUMBER: 0001062993-23-009245 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230413 FILED AS OF DATE: 20230417 DATE AS OF CHANGE: 20230417 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KIM DENNIS D CENTRAL INDEX KEY: 0001456750 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36500 FILM NUMBER: 23825148 MAIL ADDRESS: STREET 1: C/O EMERALD BIOSCIENCE, INC. STREET 2: 130 NORTH MARINA DRIVE CITY: LONG BEACH STATE: CA ZIP: 90803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc. CENTRAL INDEX KEY: 0001042074 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943103561 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7575 GATEWAY BOULEVARD STREET 2: SUITE 110 CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-293-8800 MAIL ADDRESS: STREET 1: 7575 GATEWAY BOULEVARD STREET 2: SUITE 110 CITY: NEWARK STATE: CA ZIP: 94560 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX, INC. DATE OF NAME CHANGE: 20090721 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX INC DATE OF NAME CHANGE: 19970710 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0407 4 2023-04-13 0001042074 CymaBay Therapeutics, Inc. CBAY 0001456750 KIM DENNIS D C/O CYMABAY THERAPEUTICS, INC. 7575 GATEWAY BLVD., SUITE 110 NEWARK CA 94560 0 1 0 0 Chief Medical Officer 0 Common Stock 2023-04-13 4 M 0 7781 4.37 A 27781 D Common Stock 2023-04-13 4 S 0 7781 8.9809 D 20000 D Common Stock 2023-04-17 4 M 0 112219 4.37 A 132219 D Common Stock 2023-04-17 4 S 0 112219 9.5397 D 20000 D Employee Stock Option (right to buy) 4.37 2023-04-13 4 M 0 7781 0 D 2031-05-16 Common Stock 7781 282119 D Employee Stock Option (right to buy) 4.37 2023-04-17 4 M 0 112219 0 D 2031-05-16 Common Stock 112219 169900 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.98 to $8.985, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.80, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The original option grant vested as to 1/4 of the underlying shares on May 17, 2022 and vests as to 1/48 of the underlying shares monthly thereafter. /s/ Paul Quinlan, as attorney-in-fact for Dennis D. Kim 2023-04-17